RT Journal Article
SR Electronic
T1 Dysregulation of tryptophan catabolism at the host-skin microbiota interface in Hidradenitis Suppurativa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.25.20181438
DO 10.1101/2020.08.25.20181438
A1 Guenin-Macé, Laure
A1 Morel, Jean-David
A1 Doisne, Jean-Marc
A1 Schiavo, Angèle
A1 Boulet, Lysiane
A1 Mayau, Véronique
A1 Goncalves, Pedro
A1 Duchatelet, Sabine
A1 Hovnanian, Alain
A1 Bondet, Vincent
A1 Duffy, Darragh
A1 Ungeheuer, Marie-Noëlle
A1 Delage, Maïa
A1 Nassif, Aude
A1 Di Santo, James P
A1 Demangel, Caroline
YR 2020
UL http://medrxiv.org/content/early/2020/09/10/2020.08.25.20181438.abstract
AB Hidradenitis Suppurativa (HS) is a chronic skin disorder of unknown etiology that manifests as recurrent, painful lesions. Cutaneous dysbiosis and unresolved inflammation are hallmarks of active HS, but their origin and interplay remain unclear. Our metabolomic profiling of HS skin revealed an abnormal induction of the kynurenine pathway (KP) of tryptophan catabolism in dermal fibroblasts correlating with the release of KP-inducing cytokines by inflammatory cell infiltrates. Notably, over-activation of the KP in lesional skin was associated with local and systemic depletion in tryptophan. Yet the skin microbiota normally degrades host tryptophan into indoles regulating tissue inflammation via engagement of the Aryl Hydrocarbon Receptor (AHR). In HS skin lesions, we detected contextual defects in AHR activation coinciding with impaired production of bacteria-derived AHR agonists and decreased incidence of AHR ligand-producing bacteria in the resident flora. Dysregulation of tryptophan catabolism at the skin-microbiota interface thus provides a mechanism linking the immunological and microbiological features of HS lesions. In addition to revealing metabolic alterations in HS patients, our study suggests that correcting AHR signaling would help restore immune homeostasis in HS skin.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Institut Pasteur (C.D., J.P.D.) via the Center for Translational Science (CRT), INSERM (U1221, C.D.; U1223, J.P.D.) and SFD. The Biomics Platform, C2RT, Institut Pasteur, Paris, France, is supported by France Genomique (ANR-10-INBS-09-09) and IBISA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This biomedical research study was approved by the French Ethics Committee, the competent health authority and the French Data Protection Agency. Study participants were identified by number. They provided written informed consent to the research, including data and biospecimen collection such as cutaneous biopsy sampling, prior to inclusion in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the findings of this study are available within the article and supplementary materials.